Literature DB >> 5020430

Interferon, antibody, and other host factors in herpes zoster.

D A Stevens, T C Merigan.   

Abstract

The influence of several factors on the course of herpes zoster was studied in 151 patients. Dissemination of zoster was associated with the presence of a concurrent disease, especially Hodgkin's disease, and/or the use of immunosuppressive therapy. Several host-immune parameters, including quantitative immunoglobulins, circulating lymphocyte counts, delayed hypersensitivity to multiple skin test antigens, and lymphocyte transformation to phytohemagglutinin did not correlate with dissemination of disease. Development of virus-specific complement-fixing antibody (CFA) was delayed in some patients with disseminated disease. Vesicle interferon (V-IF) titers were low early in the disease in patients with localized and disseminated zoster and then rose, usually abruptly, to a peak value and declined as pustulation and crusting occurred. However, titers in patients with localized disease rose at an earlier time. This could be seen in terms of time to development of intermediate values of V-IF or by the day on which the sharpest rise occurred. In 15 carefully studied patients with disseminated disease, the development of the maximum V-IF response was followed within 48 hr by cessation of dissemination. Half of the patients in this group had no CFA detectable until after dissemination had ceased. These findings suggest at least two host factors whose interaction might determine host response to zoster; local interferon production (possibly mediated by sensitized lymphocytes) and humoral antibody, acting to prevent or shorten dissemination of an initially local disease.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 5020430      PMCID: PMC292247          DOI: 10.1172/JCI106910

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  27 in total

1.  The development of immunoglobulin levels in man.

Authors:  M Allansmith; B H McClellan; M Butterworth; J R Maloney
Journal:  J Pediatr       Date:  1968-02       Impact factor: 4.406

2.  Immunological relationship between herpes simplex and varicella-zoster viruses demonstrated by complement-fixation, neutralization and fluorescent antibody tests.

Authors:  N J Schmidt; E H Lennette; R L Magoffin
Journal:  J Gen Virol       Date:  1969-04       Impact factor: 3.891

3.  Stimulating interaction between viruses (stimulons).

Authors:  C Chany; C Brailovsky
Journal:  Proc Natl Acad Sci U S A       Date:  1967-01       Impact factor: 11.205

4.  Serologic and virus-isolation studies of patients with varicella or herpes-zoster infection.

Authors:  E Gold
Journal:  N Engl J Med       Date:  1966-01-27       Impact factor: 91.245

5.  Immunofluorescent staining in the laboratory diagnosis of varicella-zoster virus infections.

Authors:  N J Schmidt; E H Lennette; J D Woodie; H H Ho
Journal:  J Lab Clin Med       Date:  1965-09

6.  Cure of Hodgkin's disease and other malignant lymphomas.

Authors:  H S Kaplan; S A Rosenberg
Journal:  Postgrad Med       Date:  1968-05       Impact factor: 3.840

7.  Impaired in vitro lymphocyte transformation in Hodgkin's disease.

Authors:  E M Hersh; J J Oppenheim
Journal:  N Engl J Med       Date:  1965-11-04       Impact factor: 91.245

8.  Inhibition of in vitro lymphocyte transformation during chemotherapy in man.

Authors:  E M Hersh; J J Oppenheim
Journal:  Cancer Res       Date:  1967-01       Impact factor: 12.701

9.  Immune specific induction of interferon production in cultures of human blood lymphocytes.

Authors:  J A Green; S R Cooperband; S Kibrick
Journal:  Science       Date:  1969-06-20       Impact factor: 47.728

10.  Effect of previous irradiation on the transformation of blood lymphocytes.

Authors:  R E Millard
Journal:  J Clin Pathol       Date:  1965-11       Impact factor: 3.411

View more
  12 in total

1.  Herpes zoster in general practice.

Authors:  C A Ross; W K Brown; A Clarke; W F Caldwell; E R Gordon; J Harvey; A M McAlister; J McGlone; R T Prentice; W Thorburn; C Tobias
Journal:  J R Coll Gen Pract       Date:  1975-01

2.  Letter: Intravenous cytarabine in treatment of herpes zoster in haematological malignancy.

Authors:  S Kernbaum
Journal:  Br Med J       Date:  1976-01-24

Review 3.  Cell-mediated immunity and its role in resistance to infection.

Authors:  E J Wing; J S Remington
Journal:  West J Med       Date:  1977-01

4.  Evaluation of topical polyinosinic acid-polycytidylic acid in treatment of localized herpes zoster in children with cancer: a randomized, double-blind controlled study.

Authors:  S Feldman; W T Hughes; R W Darlington; H K Kim
Journal:  Antimicrob Agents Chemother       Date:  1975-09       Impact factor: 5.191

5.  Pathogenesis of Rift Valley fever in rhesus monkeys: role of interferon response.

Authors:  J C Morrill; G B Jennings; A J Johnson; T M Cosgriff; P H Gibbs; C J Peters
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

6.  Selective increase in lymphocyte interferon response to vaccinia antigen after revaccination.

Authors:  L B Epstein; D A Stevens; T C Merigan
Journal:  Proc Natl Acad Sci U S A       Date:  1972-09       Impact factor: 11.205

7.  Spontaneous and antibody-dependent cellular cytotoxicity by lymphocyte subpopulations in peripheral blood and spleen from adult untreated patients with Hodgkin's disease.

Authors:  S Gupta; G Fernandes
Journal:  Clin Exp Immunol       Date:  1981-07       Impact factor: 4.330

8.  Cell-mediated and humoral immunity to herpesviruses during and after herpes zoster infections.

Authors:  O S Sørensen; S Haahr; A Møller-Larsen; K Wildenhoff
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

Review 9.  Risks for infection in patients with asthma (or other atopic conditions): is asthma more than a chronic airway disease?

Authors:  Young J Juhn
Journal:  J Allergy Clin Immunol       Date:  2014-08       Impact factor: 10.793

10.  Pathogenesis of herpes simplex labialis: correlation of vesicle fluid interferon with lesion age and virus titer.

Authors:  S L Spruance; J A Green; G Chiu; T J Yeh; G Wenerstrom; J C Overall
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.